The scientist-turned-banker’s mission to fund cancer breakthrough
Alan Taylor has swapped his early years on the sports field and a stint as an investment banker for the boardroom, in his quest to get medical breakthroughs to patients.
When Alan Taylor was growing up in a 1970s public housing estate in Sydney, he would spend clear nights glued to a telescope gazing to the heavens from his perch on the 14th floor.
His humble upbringing in one of the city’s roughest neighbourhoods of Waterloo was the unlikely foundation for his career as a scientist-turned-investment banker who now chairs one of Australia’s fastest-growing biotechs, Clarity Pharmaceuticals. The clinical-stage $1.3 billion company is pioneering new cancer treatments using copper radioisotopes which it hopes will be on the market in the next two years.
Loading...
Michael Smith is the health editor for The Australian Financial Review. He is based in Sydney. Connect with Michael on Twitter. Email Michael at michael.smith@afr.com
